Advanced ICU Care®, Inc., the nation’s largest provider of telemedicine solutions to hospital intensive care units (ICU), today announced the addition of full service operations centers in the Houston, Texas, and Irvine, California, markets.
Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR), the public company enjoying a meteoric jump in its stock price, announced after the close of markets Tuesday that it has completed a secondary public offering of stock at $100 a share, raising net proceeds of $189.9 million.
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.
Cardiac Dimensions® today announced the addition of $15.2 million to its previously announced financing.
If you’re one of those fixated on the bottom line, 2014 might seem like a tough year for Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR).
The drug development company released earnings at the end of the day Thursday, March 5th for the fourth quarter that ended Dec. 31 and for the full year. Losses were up for the year from $26.1 million to $36.4 million, while losses for the quarter were about flat compared to the fourth quarter of 2013, going from $9.7 million to $9.5 million.